Company intelligence / Profile preview

Barinthus Biotherapeutics

Ownership: Public · BRNS
Employees: ~100
Development stage: Other

Overview

Barinthus Biotherapeutics has a focused clinical pipeline built around three proprietary platforms—ChAdOx, MVA, and SNAP. Its lead programs include VTP‑300 for chronic hepatitis B in Phase 2b with positive interim data reported in June 2024; VTP‑1000 for celiac disease in a Phase 1 trial with single ascending dose data expected mid‑2025; and VTP‑850 for recurrent prostate cancer in a Phase 1 trial. The company recently prioritized its pipeline to focus on autoimmune diseases using the SNAP-TI platform.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Viral vector-based immunotherapies (ChAdOx, MVA)Synthetic nanoparticle platforms (SNAP-TI for tolerance immunotherapy, SNAP-CI for cancer immunotherapy)
Industry: Biotech

Drug pipeline

21 assets

ChAdOx1-HBV

20 more assets in the full pipeline.

Partnerships

Not specifically detailed in recent sources; historically partnered with University of Oxford on COVID vaccine development as Vaccitech

Beyond the preview

Go deeper on Barinthus Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Barinthus Biotherapeutics.